1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Jonathan Brammer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Ruxolitinib - T-Cell Large Granular Lymphocyte Leukemia | Phase 2 | Recruiting | Jonathan Brammer | 30 | 2023-05-03 | 2026-10-01 |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
Leukemia, Large Granular Lymphocytic (2)
Azacitidine (1) · cc-486 (1) · ruxolitinib (1)
United States (2)